Next Article in Journal
Ochrobactrum anthropi Septic Arthritis: Case Report and Implications in Orthopedic Infections
Previous Article in Journal
Salmonella typhimurium epidural Empyema in an HIV Infected Patient
 
 
Infectious Disease Reports is published by MDPI from Volume 12 Issue 3 (2020). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with PAGEPress.
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

In vitro Activity of Tigecycline Against Patient Isolates Collected during Phase 3 Clinical Trials for Hospital Acquired Pneumonia

Infectious Diseases, Biosynthetic Chemistry, Wyeth Research, Pearl River, NY, USA
*
Author to whom correspondence should be addressed.
Infect. Dis. Rep. 2010, 2(1), e1; https://doi.org/10.4081/idr.2010.e1
Submission received: 29 October 2009 / Revised: 7 January 2010 / Accepted: 11 January 2010 / Published: 2 February 2010

Abstract

The in vitro activity of tigecycline was evaluated against 819 baseline pathogens isolated from 383 patients enrolled in the phase 3 clinical trial investigating the efficacy of tigecycline in hospital acquired pneumonia (HAP). The trials were global, enrolling patients in 27 countries. Tigecycline was active against the most prevalent pathogens in HAP, including gram-positive and gram-negative strains (90% of MICs ≤2 μg/mL for the entire collection). The spectrum of activity of tigecycline included important pathogens such as Staphylo- coccus aureus (including methicillin-resistant S. aureus), Enterococcus faecalis, Streptococcus pneumoniae, Acinetobacter baumannii/calcoaceticus complex, Escherichia coli, Klebsiella pneumonia, and Enterobacter cloacae. As reported previously, a few genera, such as Pseudomonas aeruginosa and the Proteeae, were generally less susceptible to tigecycline by comparison to other gram-negative pathogens. The excellent in vitro, expanded, broad-spectrum activity of tigecycline in the clinical isolates confirmed the potential utility of tigecycline for pathogens associated with with hospital acquired pneumonia infections.
Keywords: Tigecycline; clinical isolates; in vitro susceptibility; MIC; hospital acquired pneumonia Tigecycline; clinical isolates; in vitro susceptibility; MIC; hospital acquired pneumonia

Share and Cite

MDPI and ACS Style

Petersen, P.J.; Tuckman, M.; Jones, H. In vitro Activity of Tigecycline Against Patient Isolates Collected during Phase 3 Clinical Trials for Hospital Acquired Pneumonia. Infect. Dis. Rep. 2010, 2, e1. https://doi.org/10.4081/idr.2010.e1

AMA Style

Petersen PJ, Tuckman M, Jones H. In vitro Activity of Tigecycline Against Patient Isolates Collected during Phase 3 Clinical Trials for Hospital Acquired Pneumonia. Infectious Disease Reports. 2010; 2(1):e1. https://doi.org/10.4081/idr.2010.e1

Chicago/Turabian Style

Petersen, Peter J., Margareta Tuckman, and Hal Jones. 2010. "In vitro Activity of Tigecycline Against Patient Isolates Collected during Phase 3 Clinical Trials for Hospital Acquired Pneumonia" Infectious Disease Reports 2, no. 1: e1. https://doi.org/10.4081/idr.2010.e1

Article Metrics

Back to TopTop